EyeGate Pharmaceuticals, Inc. Appoints Brian M. Strem, Ph.D. as President
July 27, 2021 at 01:48 am IST
Share
On July 23, 2021, the Board of Directors (the “Board”) of EyeGate Pharmaceuticals, Inc. (the “Company”) appointed Brian M. Strem, Ph.D. as President of the Company, effective as of July 26, 2021 (the “Effective Date”). Dr. Strem is a co-founder of Yellowbrick Bio LLC d/b/a Bayon Therapeutics (“Bayon”), an ophthalmological pharmaceutical company based on a novel, light responsive small molecule platform. In connection with the appointment of Dr. Strem, Franz Obermayr, Ph.D., who has served as the Company’s Acting Chief Executive Officer since February 2021, resumed his prior role with the Company as its EVP Clinical Development, effective as of the Effective Date.
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).
KIORA PHARMACEUTICALS, INC. 
